Key Findings
- Analysis of Caris molecular profiling data from 10,041 lung adenocarcinomas showed that low LIF and high LIFR expression were associated with distinct immune microenvironment states and improved survival, with additional LIF-associated survival differences in osimertinib-treated EGFR-mutant tumors.
- In this study, integrated genomic, transcriptomic, and immune profiling was shown to refine molecular classification and identify clinically relevant biomarkers of therapeutic response and prognosis in NSCLC.